PHA Pharmagest Interactive SA

Equasens: Appointment at the head of the Pharmagest Division

Equasens: Appointment at the head of the Pharmagest Division

Villers-lès-Nancy (France), July 03, 2025 – 06 :00pm (CET)

Press Release

Equasens announces the departure of Damien VALICON, as Deputy Chief Executive Officer and Director of the Pharmagest Division

He will be replaced by François-Pierre MARQUIER as Director of the Pharmagest Division.

***

(Euronext Paris™ - Compartment B - FR 0012882389 –$EQS), announces the departure of Damien VALICON, who held the position of Deputy Chief Executive Officer and Director of the Pharmagest Division for 18 months, and the appointment of François-Pierre MARQUIER, who is resuming his operational duties as Director of the Pharmagest Division.

The appointment of François-Pierre MARQUIER, proposed by Denis SUPPLISSON, Chief Executive Officer of the Equasens Group, will be effective after a transition period. It was approved by the Board of Directors at its meeting on June 25, 2025, chaired by Thierry CHAPUSOT, Chairman of the Board of Directors.

François-Pierre MARQUIER, who joined Pharmagest in May 2021 as Regional Director for the Ile-de-France region, has headed the Pharmacy France business since January 2023. He will now oversee all the Division's activities, both in France and the rest of Europe.

Denis SUPPLISSON, Chief Executive Officer of Equasens Group, states: « François-Pierre has a deep understanding of our business sectors, a precise grasp of our challenges and the sectoral expertise we need to accelerate our European development. »

Biography François-Pierre MARQUIER -  - Graduate of IDRAC Business School and Emlyon Business School (DUA), he began his career in 1996 with DHL as Marketing Manager. In 2000, he joined Cegid Group where he evolved for over 20 years, holding management positions in marketing and sales.

He joined Equasens Group in May 2021 as Regional Director, before being appointed Director of the Pharmacy France business in January 2023.

He has represented Pharmagest within FEIMA for over 2 years.

Upcoming financial communications

  • 31 July 2025:                 Q2 2025 revenue - After the close of trading
  • 26 September 2025:         H1 2025 results

About - Follow us also on

Founded over 35 years ago, Equasens Group, a leader in digital healthcare solutions, today employs over 1.400 people across Europe.

Equasens Group’s specialized business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as data hosting, financing and training adapted to their specific needs.

And reflecting the spirit of its tagline "Technology for a More Human Experience", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient and secure healthcare system.

Listed on Euronext Paris, Equasens Group (Compartment B - FR 0012882389 – $EQS) applies a two-pronged development strategy combining organic growth with targeted acquisitions at a European level.

CONTACTS

Analyst and Investor Relations:

Chief Administrative and Financial Officer: Frédérique Schmidt

Tel: +33 (0)3 83 15 90 67 -

Financial communications agency:

FIN’EXTENSO - Isabelle Aprile

Tel.: +33 (0)6 17 38 61 78 –

Attachment



EN
03/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharmagest Interactive SA

 PRESS RELEASE

EQUASENS : Mise à disposition du rapport financier semestriel 2025

EQUASENS : Mise à disposition du rapport financier semestriel 2025 Villers-lès-Nancy, le 30 septembre 2025 - 18h00 (CET) COMMUNIQUE DE PRESSE EQUASENS annonce la publication de son rapport financier semestriel au 30 juin 2025 EQUASENS annonce que son rapport financier semestriel 2025 a été déposé auprès de l’Autorité des Marchés Financiers (AMF) en date du 30 septembre 2025. Ce document est disponible sur le site Internet de l’AMF ainsi que sur celui d’EQUASENS : (Rubrique INVESTISSEURS / Section INFORMATION RÉGLEMENTÉE). Ce rapport financier semestriel est composé de la déclaration...

 PRESS RELEASE

EQUASENS : Bilan S1 2025 contrat de liquidité

EQUASENS : Bilan S1 2025 contrat de liquidité Villers-lès-Nancy, le 29 septembre 2025 - 08h00 (CET) COMMUNIQUE DE PRESSE BILAN SEMESTRIEL S1-2025 DU CONTRAT DE LIQUIDITECONTRACTE AVEC LA SOCIETE DE BOURSE GILBERT DUPONT Au titre du contrat de liquidité confié par la société EQUASENS à la Société de Bourse Gilbert Dupont, à la date du 30 juin 2025, les moyens suivants figuraient au compte de liquidité : Nombre d’actions : 3 540Solde en espèces : 55 775,07 €. Au cours du 1er semestre 2025, il a été négocié un total de : ACHAT59 121 titres2 428 700,43 €2 337 transactionsVENTE58 884 titr...

Arnaud Riverain
  • Arnaud Riverain

EQUASENS (EQS) - Résultats S1 : Les investissements se poursuivent / A...

CA S1 116 M€ +7,4% ROC 21,1 M€ +1,2% / Marge opérationnelle courante 18,2% vs 19,3% au S1 2024 RN 18,1 M€ stable / Marge nette 15,6% vs 16,7% Dette financière nette -98,8 M€ / Gearing -41,3% vs -33,1% au 31/12/24 CA S2 attendu en progression de près de +10%

 PRESS RELEASE

Equasens: 2025 half-year results

Equasens: 2025 half-year results Villers-lès-Nancy, 26 September 2025 - 6:00 PM (CET) PRESS RELEASE 2025 half-year results Revenue: €116.0m (+7.4% reported and +6.4% like-for-like)Recurring EBITDA: €29.8m (+5.5%)Current Operating Profit €21.1m (+1.2%) Net Profit: €18.1m (+0.3%)Net Financial Surplus : €98.8m (+€19.2m / 31-12-2024) H1 2025 RESULTS(M€)2024Reported basis2025Reported basisChange / Reported basisRevenue108.0116.08.07.4%Recurring EBITDA28.229.81.55.5%Recurring EBITDA / Sales26.1%25.7%  Current operating profit20.921.10.21.2%COP / Sales19.3%18.2%  Net Profit18.118.10.00.3%Net ...

 PRESS RELEASE

EQUASENS : Résultats semestriels 2025

EQUASENS : Résultats semestriels 2025 Villers-lès-Nancy, le 26 septembre 2025 - 18h00 (CET) COMMUNIQUE DE PRESSE Résultats semestriels 2025 Chiffre d'affaires : 116,0 M€ (+7,4% en publié et +6,4% en organique)EBITDA courant : 29,8 M€ (+5,5%)Résultat Opérationnel Courant : 21,1 M€ (+1,2%) Résultat Net : 18,1 M€ (+0,3%)Excédent financier net : 98,8 M€ (+19,2 M€ / 31-12-2024) RESULTATS S1 2025 (M€)Publié 2024Publié 2025Variation/publiéChiffre d'affaires108,0116,08,07,4%EBITDA courant28,229,81,55,5%EBITDA courant / CA26,1%25,7%  ROC20,921,10,21,2%ROC / CA19,3%18,2%  Résultat Net18,118,10,0...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch